- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:30 | SenzaGen AB: Report from AGM of SenzaGen AB on 12 May 2026 | 79 | GlobeNewswire (Europe) | The Annual General Meeting (AGM) of SenzaGen held on today's date, 12 May 2026 in Lund, resolved to pass all proposals presented by the board and shareholders.
Adoption of income statement and balance... ► Artikel lesen | |
| 07:30 | SenzaGen AB: SenzaGen's interim report January-March 2026 | 10% sales growth alongside increased attention to non-animal methods | 75 | GlobeNewswire (Europe) | Message from the CEO"We started the year with 10 percent growth despite negative foreign exchange effects and the impact of a subsidiary undergoing a transition. At the same time, we maintained our... ► Artikel lesen | |
| 15.04. | SenzaGen AB: SenzaGen's subsidiary receives strategically important order | 154 | GlobeNewswire (Europe) | SenzaGens's subsidiary VitroScreen has received an order from an existing customer for non-animal efficacy testing. The order includes studies using the proprietary platform VitroScreenORA® and is carried... ► Artikel lesen | |
| 31.03. | XFRA NEW INSTRUMENTS AVAILABLE ON 31.03.2026 | 402 | Xetra Newsboard | The following instruments on XETRA do have their first trading 31.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 31.03.2026
Aktien
1 SE0009697204 Boho Group AB
2 SE0008321608... ► Artikel lesen | |
| 30.03. | SenzaGen AB: SenzaGen wins new global cosmetics group as customer | 171 | GlobeNewswire (Europe) | SenzaGen has received a first order from a leading global group in the cosmetics sector, one of the company's prioritized industry segments. The customer will begin by testing with GARD®skin Dose-Response... ► Artikel lesen | |
| 13.02. | SenzaGen AB: SenzaGen carries out a directed issue of approximately SEK 17.5 million to the institutional investor Eiffel Investment Group | 144 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 13.02. | SenzaGen AB: SenzaGen's Year-End Report 2025 | SenzaGen closes the year with continued strong GARD sales | 166 | GlobeNewswire (Europe) | Message from the CEO
"As previously stated in the half-year report, 2025 performance was stronger in the second half of the year. GARD® continued to strengthen its market position with positive sales... ► Artikel lesen | |
| 16.12.25 | SenzaGen AB: SenzaGen further strengthens US market position with 1.5 MSEK order from global chemical industry leader | 175 | GlobeNewswire (Europe) | SenzaGen continues to solidify its role as an important partner for customers with high safety testing requirements, securing an assignment worth approximately 1.5 MSEK from a leading American chemical... ► Artikel lesen | |
| SENZAGEN Aktie jetzt für 0€ handeln | |||||
| 20.11.25 | SenzaGen AB: SenzaGen opens expanded laboratory facilities to strengthen capacity in line with 2030 growth plan | 174 | GlobeNewswire (Europe) | To support its recently announced growth strategy through 2030, SenzaGen has opened expanded office and laboratory facilities in Lund. This investment strengthens the company's ability to meet the growing... ► Artikel lesen | |
| 18.11.25 | SenzaGen AB: UK signals shift to non-animal testing - new opportunities for SenzaGen | 187 | GlobeNewswire (Europe) | The UK government has recently unveiled a national strategy to accelerate the phase-out of animal testing in research and product development. The plan includes clear timelines and governance to ensure... ► Artikel lesen | |
| 05.11.25 | SenzaGen AB: SenzaGen's interim report January-September 2025 | Growth and break-even in Q3 | 161 | GlobeNewswire (Europe) | Message from the CEO"We delivered a strong third quarter in line with our expectations, with higher sales and significantly improved EBITDA, both sequentially and year on year, which I am pleased to... ► Artikel lesen | |
| 22.08.25 | SenzaGen AB: SenzaGen secures new follow-up order worth approx. 1.0 MSEK for GARD from a global leading U.S. pharmaceutical company | 222 | GlobeNewswire (Europe) | SenzaGen has received a new follow-up order from a global leader in the pharmaceutical and life science industry. The order, valued at approximately 1.0 million SEK, covers testing with GARD®air, SenzaGen's... ► Artikel lesen | |
| 20.08.25 | SenzaGen AB: SenzaGen's interim report January-June 2025 | Strong order intake and expanded OECD approval for GARDskin | 331 | GlobeNewswire (Europe) | Message from the CEO
"We continue to win new customers, and our order intake is significantly higher than our sales for the period, giving us a strong starting position for the coming quarters. Given... ► Artikel lesen | |
| 30.06.25 | SenzaGen AB: SenzaGen obtains expanded OECD approval for GARDskin - further strengthens position in non-animal regulatory testing | 341 | GlobeNewswire (Europe) | SenzaGen's non-animal test method GARD®skin, which has been approved since 2022 under OECD Test Guideline TG 442E, has now also been included in the newly introduced OECD TG 497. This international... ► Artikel lesen | |
| 24.06.25 | SenzaGen AB: SenzaGen receives new assignment worth 1.5 MSEK from RIFM for continued collaboration in photosensitization testing | 225 | GlobeNewswire (Europe) | SenzaGen has been awarded a new grant worth 1.5 MSEK from the Research Institute for Fragrance Materials (RIFM), a leading international research institute in fragrance safety. The assignment involves... ► Artikel lesen | |
| 14.05.25 | SenzaGen AB: Report from AGM of SenzaGen AB on 14 May 2025 | 315 | GlobeNewswire (Europe) | The Annual General Meeting (AGM) of SenzaGen held on today's date, 14 May 2025 in Lund, resolved to pass all proposals presented by the board and shareholders.
Adoption of income statement and balance... ► Artikel lesen | |
| 14.05.25 | SenzaGen AB: SenzaGen's interim report January-March 2025: High activity amid global turbulence - building for growth | 242 | GlobeNewswire (Europe) | Message from the CEO"The quarter was shaped by a volatile global environment, adverse foreign exchange effects, and longer customer decision cycles, which have together impacted sales growth and consequently... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,800 | +2,27 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 109,03 | -14,54 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| ERNEXA THERAPEUTICS | 12,150 | +68,52 % | Ernexa Therapeutics Inc.: Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models | CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 343,62 | +3,56 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| MODERNA | 45,405 | +1,11 % | Moderna: Hantavirus-Schlagzeilen treiben Impfstoff-Aktie an | Das Hantavirus ist auf einem kleinen Kreuzfahrtschiff im Atlantik ausgebrochen. Die Weltgesundheitsorganisation (WHO) hat inzwischen fünf von acht Verdachtsfällen als offizielle Fälle bestätigt. Aus... ► Artikel lesen | |
| CG ONCOLOGY | 72,05 | +3,94 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates | Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant... ► Artikel lesen | |
| ADMA BIOLOGICS | 8,400 | +6,60 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 16,170 | +9,78 % | CGEM Forum Reveals Only 6,000 Moroccan Firms Export, a Path to Change chartered | ||
| ARCUTIS BIOTHERAPEUTICS | 20,700 | -2,54 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| BIONTECH | 79,70 | +0,63 % | BioNTech zieht Konsequenzen nach höherem Verlust: Vier Werke dicht | BioNTech hat am Dienstag Zahlen für das erste Quartal 2026 vorgelegt. Das Biotechnologie-Unternehmen aus Mainz erzielte im ersten Quartal 2026 Umsatzerlöse von 118,1 Millionen Euro, nach 182,8 Millionen... ► Artikel lesen | |
| ERASCA | 10,390 | -0,48 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| EVOTEC | 5,080 | -2,31 % | Evotec im Umbau: Verlust steigt, Strategie-Prüfung läuft | Das Biotech-Unternehmen Evotec erzielte im ersten Quartal 2026 einen Konzernumsatz von 156,6 Millionen Euro, nach knapp 200 Millionen Euro im Vorjahreszeitraum. Der Rückgang erklärt sich nach ANgaben... ► Artikel lesen | |
| NUVALENT | 102,64 | -1,83 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,960 | +1,61 % | H.C. Wainwright cuts Summit Therapeutics stock price target on trial risk | ||
| COGENT BIOSCIENCES | 34,530 | +1,26 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen |
SENZAGEN AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,35 % bei einem Aktienkurs von 0,484 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SENZAGEN AB finden Sie auf Wallstreet Online.